Gate to Wellness

Gate Bioscience is a preclinical biotechnology company pioneering a novel therapeutic approach called "Molecular Gating." The company's platform focuses on developing small molecules that bind to the Sec61 translocon, a universal channel through which nearly all secreted and membrane proteins must pass to enter the secretory pathway. By specifically blocking the passage of individual disease-causing proteins while leaving others unaffected, Gate Bioscience aims to treat a wide range of conditions, including inflammatory and neurodegenerative diseases. Launched in 2023 with significant venture backing, the company is positioned to create a new class of medicines that eliminate pathogenic proteins at their source.